Betta Pharmaceuticals

• Active pipeline of 30 oncology programs across Phase 1-4 with depth in lung cancer, including Phase 3 assets (Befotertinib + Icotinib, Icotinib monotherapy) that represent near-term value catalysts
• Focus on clinically validated mechanisms (EGFR inhibitors, ALK inhibitors) in high-prevalence Asian oncology markets with strong unmet need
• Opportunity to contribute to Chinese biotech scaling in oncology, an area where Betta has execution history with multiple Phase 4 programs

Generated by Claude from Betta Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Phase 2-3 candidate with Phase 3 combination study (Befotertinib + Icotinib placebo) in NSCLC, representing near-term catalyst potential.